Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Earnings: Teva Moves On With Russia, LatAm In Focus

This article was originally published in PharmAsia News

Executive Summary

Teva appears to have eased past a management shakeup and extended its lead in Copaxone with the company ready to expand in emerging markets as the next frontier, led by Russia and Latin America.

You may also be interested in...



Teva’s Focus On Its Core Means Increased Outlicensing Action

Teva’s recent restricting has the firm focusing internal R&D on CNS and respiratory therapies, with plans to out-license or creatively finance development of non-core pipeline assets.

Teva’s New Copaxone Gaining Market Share Ahead Of Generics

With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Topics

Related Companies

UsernamePublicRestriction

Register

SC086058

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel